HR = 0.19 That's remarkable. And this is not against a placebo. The $PFE study compared Lorbrena against Xalkori.

Lorbrena is not a big drug for Pfizer's bottom line, but it certainly means a lot to patients with ALK-positive lung cancer. #ASCO24

For one rare type of lung cancer, Pfizer $PFE pill reduces progression by 81% statnews.com/2024/05/31/pfi… via Matthew Herper #ASCO24

Only tweet for #ASCO24
The response rate for Gem-Abraxane in #PancreaticCancer was 48% in the Phase1b/2 & less than half (23%) in the Phase 3 (real world it’s more like 30%).
Bottom line - early phase trials are carefully selected patients for many reasons. Healthy skepticism is

Like I said

This would be a good time to drop bad news…

Ultragenyx $RARE gene therapy for rare liver ailment succeeds in late-stage trial statnews.com/2024/05/30/ult… via Jason Mast

This week's Biotech Scoreboard newsletter:

⚽️ Did Sarepta Therapeutics $SRPT earn $4 billion from exon-skipping drugs that don’t work?

☕️ A chat with biotech fund manager Rod Wong

statnews.com/2024/05/30/sar…

Updated with comments from CEO Vlad Coric:

$BHVN Biohaven protein-degrader drug falls short of investor expectations in early-study test statnews.com/2024/05/29/bio…

$BHVN Biohaven protein-degrader drug falls short of investor expectations in early-study test statnews.com/2024/05/29/bio…

$BHVN just issued a press release on a drug that is NOT BHV-1300, its IgG protein degrader. This is weird.

Looking to expand its pipeline, Merck $MRK to buy eye-disease startup EyeBio statnews.com/2024/05/29/mer… via Andrew Joseph

$MRUS $300m offering

$INSM Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials statnews.com/2024/05/28/ins… via Andrew Joseph

$MRUS Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer statnews.com/2024/05/28/mer…

The new petosemtamab update for #ASCO24 - with some important data still withheld for June 3 presentation.